Emergent BioSolutions | EBS - Sales Revenues


Emergent BioSolutions reported $276.6M in Sales Revenues for its fiscal quarter ending in December of 2023.





Sales Change Date
Acadia Pharmaceuticals USD 307.96M 39.9M Jun/2026
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
ALKERMES USD 496.01M 103.1M Jun/2026
Alnylam Pharmaceuticals USD 1.29B 120M Jun/2026
Amarin USD 49.22M 451K Dec/2025
ANI Pharmaceuticals USD 237.5M 9.56M Mar/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Emergent BioSolutions USD 276.6M 6.1M Dec/2023
Exelixis USD 610.8M 12.14M Mar/2026
Glaxosmithkline GBP 10.09B 1.37B Mar/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Ionis Pharmaceuticals USD 268M 22M Jun/2026
Ironwood Pharmaceuticals USD 106.51M 58.8M Mar/2026
Lexicon Pharmaceuticals USD 5.49M 8.69M Dec/2025
Lonza CHF 3.58B 63M Jun/2025
Merck USD 16.6B 310M Jun/2026
Moderna USD 100M 289M Jun/2026
Myriad Genetics USD 190.7M 9.7M Jun/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 959M 148M Jun/2026
Pacira USD 192.4M 15.4M Jun/2026
Pfizer USD 15.03B 530M Jun/2026
PTC Therapeutics USD 361M 88M Jun/2026
Sanofi EUR 11.95B 710M Jun/2026
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
United Therapeutics USD 783.3M 1.8M Jun/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024